Track exporter growth in real time. Surface the fastest-rising suppliers, the molecule baskets they are entering, and the contracting names worth a second look.
Aggregate observable trade value grew from $7.13B in 2023 to $8.29B in 2024, a 16.3% YoY lift. The 2024 to 2025 cycle then cooled to 9.5%. Across companies with two-year coverage, the median 2024 YoY was +15.0% with 235 of 353 exporters in positive territory; in 2025 the median cooled to +3.7%.
All active exporters with at least $30M annual trade. Or scope to a portfolio: only suppliers serving the molecules you source today.
Year-over-year USD growth, molecule-count delta, destination-count delta. Three signals per exporter, computed at the warehouse layer.
Citation-anchored brief with the top-20 fastest growers, the molecules they entered, and a one-click handoff to BD or procurement outreach.
A supplier growing 500% is adding capacity. Engage them before the next-tier buyers lock up their next plant expansion.
Filter to suppliers that entered your molecules in the last 12 months. These are pre-qualified second-source candidates with proven trade history.
USD value, molecule count, destination count. A 200% USD growth on the same molecule set is different from 200% on three new molecules.
Contracting suppliers are flagged separately. A 30% drop combined with an OAI inspection is the distressed-asset signal that BD wants.
A real chat thread in PharmaDB. Type a question, the AI agent runs the tools, the answer lands as a saveable note.
pharmagraph_query Twelve exporters with at least $30M trade in 2024 and a positive YoY signal · growth normalised to 0 to 1 scale for the heatmap.
The YoY growth board is the supplier radar for procurement and BD. PharmaDB ranks 1,800+ active exporters by year-over-year trade growth, surfaces the molecule and destination deltas, and refreshes weekly. The view is company_trade_growth; the join is to global_companies. The hero molecule example tied to this signal is dulaglutide, where the active exporter cohort widened in 2024.
Sum of declared export value for the exporter in the latest full year divided by the prior full year, expressed as a percentage. Exporters with under $1M in either year are excluded as noise. The view is company_trade_growth.
It signals capacity coming online faster than peers can absorb. A buyer who engages before the supplier's order book fills locks in better pricing and a longer queue position. APITORIA, Neuland, and Blue Jet all hit this in 2024.
Yes. The same query surfaces the bottom of the league table. A 30% YoY decline combined with an OAI inspection is the distressed-asset signal that the BD and M&A workflows consume.
The spend cube is the static inventory of who exports what. The growth dashboard is the time-derivative on top: who is accelerating, who is decelerating. They share the same exporter universe.
Yes. Pass a molecule list or a destination list and the AI agent filters the exporter universe before computing growth. The result becomes a portfolio-relevant supplier radar rather than a global league table.
Trade aggregates refresh weekly. Growth deltas recompute on every refresh. The catalog row carries the last-computed timestamp surfaced on every result page.
Bring the molecule, the lane, or the supplier you're sourcing this week. The AI agent runs it on PharmaDB in 30 minutes. You keep the brief.